Delivery System to Increase Adherence to Myofunctional Therapy Protocol

项目摘要/摘要 拟议的项目重点是创造一种肌功能疗法的交付方法，旨在 提高用户参与度并遵守治疗方案。意义：睡眠呼吸暂停影响22 美国有100万人，80%的人患有中度或严重的睡眠障碍 呼吸暂停尚未得到诊断或治疗。未经治疗的睡眠呼吸暂停症对经济的影响几乎是 1500亿美元。常见的治疗方法，如CPAP设备、牙科器械和外科干预措施 昂贵、不舒服或侵入性的，导致大量未接受治疗的个体，即使在 正确的诊断。肌功能疗法已被证明是一种有效的联合疗法，可以改善现有的 睡眠呼吸暂停的治疗和治疗不舒服时睡眠呼吸暂停的有效替代方法 设备或侵入性手术是患者不能容忍的。然而，获得肌功能治疗的途径是 仅限于由专家指导的治疗过程以及对肌功能治疗方案的坚持 没有指导的设置可能会很困难。医疗保健系统越来越多地通过智能手机提供治疗 应用程序，以改善访问和遵守情况。假设：我们假设肌功能 治疗可以通过交互式智能手机应用程序提供，依从率合理。 具体目标：为了在第一阶段证明拟议系统的可行性，IDL及其合作者将：(1) 开发有效治疗阻塞性睡眠呼吸暂停的游戏化肌肉功能治疗方案(2)开发交互式 治疗传递系统和(3)在使用所开发的系统时测试对协议的依从性。

Project Summary/Abstract The proposed project focuses on creating a delivery method for myofunctional therapy that is designed to increase user engagement and adherence to the therapy protocol. Significance: Sleep apnea affects 22 million people in the U.S. and 80% of the individuals who suffer from moderate or Severe Obstructive Sleep Apnea have not received diagnosis or treatment. The economic impact of untreated sleep apnea is nearly $150 billion. Common treatments such as CPAP devices, dental appliances, and surgical interventions are expensive, uncomfortable, or invasive, resulting in large number of untreated individuals even when there is a proper diagnosis. Myofunctional therapies have been proven to be an effective co-therapy to improve existing treatments for sleep apnea and an effective alternative method for treating sleep apnea when uncomfortable devices or invasive procedures are not tolerated by the patient. However, access to myofunctional therapy is limited to guided therapy sessions by specialists and the adherence to the myofunctional therapy protocol in an unguided setting can be difficult. Healthcare systems are increasingly delivering therapies through smartphone applications in order to improve access and adherence. Hypothesis: We hypothesize that myofunctional therapies can be delivered through an interactive smartphone application with reasonable adherence rates. Specific Aims: To prove feasibility of the proposed system in Phase I, IDL and its collaborators will: (1) Develop a gamified myofunctional therapy protocol effective for OSA treatment (2) Develop an interactive therapy delivery system and (3) Test the adherence to the protocol while using the developed system.